Oricula Therapeutics LLC Company Profile
Privately held Oricula Therapeutics, LLC, headquartered in Seattle, Wash., is one of the first biotech companies focused on introducing medications to preserve hearing and balance from the damaging effects of medications and aging. Founded in 2013, Oricula is commercializing research conducted at the University of Washington and it holds exclusive license to the resulting intellectual property. This uniquely positions Oricula to introduce the first medication to be FDA-approved to prevent hearing loss for patients undergoing aminoglycoside antibiotic treatment by protecting the sound-sensing hair cells in the inner ear that are necessary for hearing. By reducing or eliminating the debilitating side effect of permanent hearing loss, Oricula hopes to open the door to wider worldwide use of valuable antibioticsin the treatment of life-threatening bacterial infections. Oricula’s first product is in pre-clinical development, progressing toward FDA Initial New Drug (IND) filing.
News from Oricula Therapeutics LLC:
Oricula Therapeutics Secures $2M National Institutes of Health Grant to Further Develop Medicine to Preserve Hearing
Grant Supports Steps Towards Investigational New Drug Filing and Clinical Trials SEATTLE, Feb. 2, 2016 /PRNewswire/ — Oricula Therapeutics, LLC, a biotech company uniquely positioned to introduce medicines to preserve hearing and balance, announced that it has received a Phase 2 Grant of $2.06 million through the Small Business Innovation Research (SBIR) Program by the National […]
Oricula Therapeutics Secures National Institutes of Health Grant to Further Develop Medicine to Preserve Hearing
Grant Supports Steps Towards Investigational New Drug Filing and Clinical Trials SEATTLE, April 30, 2014 /PRNewswire/ — Oricula Therapeutics, LLC, a biotech company uniquely positioned to introduce medicines to preserve hearing, announced that it has received a grant of $169,398 through the Small Business Innovation Research Program by the National Institute on Deafness and Other Communication […]
Oricula Therapeutics Secures Intellectual Property and Takes First Step to Commercialize Medicine to Preserve Hearing Licensing Agreement with University of Washington
Secures Intellectual Property Rights SEATTLE, April 9, 2014 /PRNewswire/ — Oricula Therapeutics, LLC, a biotech company uniquely positioned to introduce medications to preserve hearing, announced that it has secured initial funding and licensed intellectual property from University of Washington. These represent key steps toward achieving the company's vision to commercialize compounds it has developed to prevent […]
